4 October 2024
HALEON PLC
("Haleon" or "the Company")
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BMX86B70
Issuer Name
HALEON PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
Pfizer Inc.
City of registered office (if applicable)
New York
Country of registered office (if applicable)
United States of America
4. Details of the shareholder
| Name | City of registered office | Country of registered office |
| State Street Nominees Limited | London | United Kingdom |
| Guaranty Nominees Limited | London | United Kingdom |
5. Date on which the threshold was crossed or reached
03-Oct-2024
6. Date on which Issuer notified
03-Oct-2024
7. Total positions of person(s) subject to the notification obligation
| % of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 15.040000 | 0.000000 | 15.040000 | 1361709764 |
| Position of previous notification (if applicable) | 22.580000 | 0.000000 | 22.580000 | |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
| Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
| Ordinary Shares GB00BMX86B70 | | 967251860 | | 10.680000 |
| Restricted ADSs | | 394457904 | | 4.360000 |
| Sub Total 8.A | 1361709764 | 15.040000% | ||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
| Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
|
| | | | |
| Sub Total 8.B1 | | | | |
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
| Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
|
| | | | | |
| Sub Total 8.B2 | | | | ||
9. Information in relation to the person subject to the notification obligation
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
| Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
|
| | | | |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
This notification relates to the sale by Pfizer Inc. ("Pfizer") of a portion of its interest in Haleon plc ("Haleon").
Pfizer sold 640,000,000 Haleon ordinary shares ("Ordinary Shares") pursuant to a secondary offering announced on 30 September 2024. In connection with the offering, and in addition to the 640,000,000 Ordinary Shares in the offering, Pfizer sold 60,526,315 Ordinary Shares to Haleon in an off-market sale in accordance with the terms of a share purchase deed between Haleon and Pfizer that was previously approved by Haleon's shareholders.
These calculations are based on Haleon's issued voting share capital of 9,053,360,882 ordinary shares with voting rights, as communicated by Haleon in their announcement on total voting rights and capital dated 3 October 2024.
Pfizer holds its ordinary shares in Haleon through (i) State Street Nominees Limited, and (ii) Guaranty Nominees Limited (in respect of its American depositary shares representing Ordinary Shares), which hold the legal title to those shares on Pfizer's behalf.
12. Date of Completion
03-Oct-2024
13. Place Of Completion
New York
Amanda Mellor, Company Secretary
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
